| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 北大医药股份有限公司是一个以研制开发、生产销售医药原料药及制剂产品为主体的专业生产经营企业,属医药行业.现已成为西部地区最重要的医药原料药生产及出口创汇企业和全国重要的原药生产基地.主营磺胺类、抗生素、维生素、解热镇痛类、喹诺酮类、抗感染类、抗焦虑类、抗结核类、抗病毒类、脑代谢用药类、降血糖类、抗过敏类、抗溃疡类等十二大类、一百多个原料及制剂品种。公司现有全部产品均已通过GMP认证,其中多个产品通过了美国FDA认证或欧洲药典员会注册登记。 公司主营业务为药品研发、生产及销售，是国家创新型试点企业、国家火炬计划重点高新技术企业、国家两化融合贯标示范企业、重庆市技术创新示范企业、重庆市专精特新企业、重庆市制造业百强企业。公司秉承“创新、责任、信任、努力”的核心价值观，以“原料制剂一体化仿创型医药科技企业”为战略定位，围绕“抗感染、镇痛类、精神类”三大核心领域重点发展医药工业，拥有完善的质量保证体系，拥有注射剂、胶囊剂、片剂、颗粒剂、口服液等丰富的生产线。公司已建立起创新药、改良型创新药、仿制药为一体的技术体系，已开展研发项目100余项，承担国家重点火炬计划、十二五重大新药创制、市级科技计划等多项重点项目，为公司新产品、新工艺、一致性评价项目等研究提供有力保障。目前，公司已构建起从药品销售、医药流通、医院集采到供应链托管等覆盖全国的医药销售网络。未来，北大医药将致力于打造全国领先的原料制剂一体化仿创型医药科技企业，成为在中国医药行业具有重要影响力的医药上市公司。 | ||||||||||||||||||||||||
| Main Business | 从事化学药品制剂的研发、生产和销售，医药流通以及医疗服务等业务 | ||||||||||||||||||||||||
| Legal Representative | 徐晰人 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 袁宇飞 | ||||||||||||||||||||||||
| Solicitors | 北京市高朋律师事务所 | ||||||||||||||||||||||||
| Auditors | 天健正信会计师事务所有限公司 | ||||||||||||||||||||||||
| Tel No | 023-67525366 | ||||||||||||||||||||||||
| Fax No | 023-67525300 | ||||||||||||||||||||||||
| Website | www.pku-hc.com | ||||||||||||||||||||||||
| sspc@pku-hc.com；zqb@pku-hc.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 16/06/1997 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.232 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.080 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 2.542 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 3.665B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |